The link between Big Pharma and the supplement industry
March 24, 2023
By Ann-Marie Roche
Dietary supplements are regulated far less than drugs. Will that change as big companies pursue both drug development and nutraceutical manufacturing?
Caption: © istock.com/Grishin Ilya
Note: Since this article was first published in Pharma R&D in July 2017, little has changed in the way the supplement industry is regulated in the United States. The FDA has made some efforts to educate the public on ingredients in supplements, updated enforcement guidelines on some harmful ingredients and issued warning letters to bad actors, but there remains little regulation (certainly nothing compared to the clinical trials and post-market surveillance crucial to pharmaceutical drug development).
While there is little expectation that supplements will ever face that level of FDA scrutiny, more meaningful oversight could be implemented. Calls for reform have included proposals such as giving the FDA greater recall authority, establishing quality control standards, and implementing a premarket review process.
When the FDA updated some of its guidelines(opens in new tab/window) for dietary supplements in 2016, many critics of the supplement (or “nutraceutical”) business were pleased to see a bit more regulation in an industry that enjoys surprisingly little oversight. Focusing on premarket safety, the guidelines state that manufacturers and distributors must notify the FDA at least 75 days before beginning to market a dietary supplement that contains a new dietary ingredient.
However, that seems like a relatively small measure, especially when you consider the massive amount of regulation that the FDA subjects the pharmaceutical industry to. In an article demystifying the differences, Felicia D Stoler of Fox News Health explains(opens in new tab/window):
In a general sense, dietary supplements fall under the purview of the FDA — where there are regulations that pertain to labeling and ‘claims.’ However, when it comes to the measurement of safety and effectiveness — as prescription drugs must do — it is not the same. The FDA does not ensure potency, purity or biologic activity of the ingredients in dietary supplements. There is no registration or clearance by the FDA before a dietary supplement goes on the market.
Perhaps one of the most shocking differences is that, while drug makers are expected to maintain strict pharmacovigilance, reporting adverse effects from supplements is entirely voluntary. Writing for Salon(opens in new tab/window), Lynn Stuart Parramore says the lack of standards opens the door for unethical business practices:
Some who promote ‘alternatives’ — the manufacturers, distributors, and sellers of supplements, aka Big Herba — take advantage of regulatory loopholes, public distrust of the medical realm, and consumer confusion to push pills and potions that may do absolutely nothing for your health, or worse.
As Harvard Health’s Patrick J Skerrett notes(opens in new tab/window), according to the terms of the Dietary Supplement Health and Education Act of 1994, supplements with established ingredients (i.e., those that had been sold in the US before 1994) can be marketed without any evidence that they are effective or safe. “Compare this hands-off approach with the strict rules and regulations for drugs,” Skerrett writes. “No drug can be sold until the FDA has proof clear proof that it is safe and effective. And every FDA-approved drug must be made to strict specifications.”
One can imagine that some pharmaceutical drug makers might fume over this situation. After all, while they take on the serious and costly work of running intensive drug trials and conducting post-market surveillance, dietary supplement makers can just grind up a few plants, put them in a bottle and then forgo responsibility. Except for one thing: the reality is that even though the regulations on pharmaceuticals and nutraceuticals are as different as night and day, the companies creating them are not.
“Increasingly, Big Pharma and Big Herba are indistinguishable,” claims Parramore. “The very same mega-companies with gigantic chemical labs that make drugs are cooking up vitamin and herbal supplements labeled with sunny terms like ‘natural’ and ‘wholesome.’ Pfizer, Unilever, Novartis, GlaxoSmithKline and other big pharmaceutical firms make or sell supplements.” While she does acknowledge there are a few small companies still in the mix, Parramore says they represent a small fraction of the total sales in the $39 billion-a-year supplement industry.
Many of these pharma companies have made the foray into supplements because it plays to their strengths while being far, far cheaper than drug development. Meanwhile, though, there are other large companies coming at it from a different direction. Nestlé has established a subsidiary, Nestlé Health Science, which, according to STAT(opens in new tab/window), brings in billions in revenue every year, largely with “high-protein nutritional shakes sold under the Boost brand and shakes and soups marketed under the Meritene brand as reducing ‘tiredness and fatigue,’ among other benefits.”
And now that they have had that much success with just shakes and soups, Nestlé Health Science has joined the pharmaceutical game. They’ve been pursuing research collaborations with biotechs and small pharmas, engaging in studies for treatments that address everything from osteoarthritis to metabolic diseases.
As big companies pursue both drug development and nutraceutical manufacturing, it seems the lines between supplements and pharmaceuticals will continue to blur. In a Forbes interview conducted by Joanne Belbey(opens in new tab/window), medical expert Dr Kevin Campbell suggests that the two really shouldn’t be approached so differently when it comes to oversight. “Supplements are the ‘Wild Wild West’ in terms of regulation, whereas I consider pharmaceuticals over-regulated,” he says. “It’s two wide extremes. I’d like to see something more in the middle, with more regulation of supplements to protect the consumer and more meaningful streamlined regulatory
Establishing a preclinical decision framework for drugs
Preclinical safety programs often follow a standard template to determine off-target effects. However, some molecule classes and targets may raise other concerns. A well-informed, well-structured workflow needs to be thorough both in terms of information sources and methodology. In this paper, Dr William B Mattes examines the preclinical workflow for pharmaceutical safety analysis.